{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:34:00Z","timestamp":1778049240617,"version":"3.51.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The management of recurrent ischemic priapism (RIP) is not clearly defined. Ketoconazole (KTZ) is used to treat RIP and produces a temporary hypogonadal state to suppress sleep-related erections (SREs), which often evolve into episodes of ischemic priapism in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>We review our experience to prevent RIP using KTZ and present our outcomes using a decreased dose regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective chart review and phone survey of 17 patients with RIP was performed. KTZ inhibits adrenal and gonadal testosterone production with a half-life of 8 hours. By suppressing testosterone levels, SREs are interrupted. We compared our previous protocol of three times daily (TID) KTZ dosing with prednisone for 6 months with our current regimen of initiating KTZ 200 mg TID with prednisone 5 mg daily for 2 weeks and then tapering to KTZ 200 mg nightly for 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The primary outcome was the prevention of RIP using KTZ. Secondary outcomes included side effects secondary to KTZ use and patient satisfaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All men experienced daily or almost daily episodes of prolonged, painful erections prior to starting KTZ. The mean number of emergency room (ER) visits per patient prior to starting KTZ was 6.5. No patient required an ER visit for RIP while on KTZ. Sixteen of 17 patients (94%) had complete resolution of priapism while on KTZ with effects noted immediately after starting therapy and no reported sexual side effects attributed to KTZ. One man stopped therapy after 4 days because of nausea\/vomiting. Fourteen of 16 men eventually discontinued KTZ after a median duration of 7 months. Twenty-nine percent reported no recurrent priapic episodes after discontinuing. A total of 78.6% had partial or complete resolution of symptoms persisting after KTZ was discontinued with a mean post-treatment follow-up of 36.7 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No reliable effective preventative therapy has been identified for RIP. In our relatively sizable single-center experience, KTZ appears to be a reasonably effective, safe, and inexpensive treatment to prevent RIP while preserving sexual function. We now recommend our tapered dose regimen listed above. After 6 months, we recommend stopping the medication as we have found a majority of patients will not need to resume nightly KTZ.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jsm.12359","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T11:21:06Z","timestamp":1385551266000},"page":"197-204","source":"Crossref","is-referenced-by-count":29,"title":["Prevention of Recurrent Ischemic Priapism with Ketoconazole: Evolution of a Treatment Protocol and Patient Outcomes"],"prefix":"10.1093","volume":"11","author":[{"given":"Michael P.","family":"Hoeh","sequence":"first","affiliation":[{"name":"Department of Urology \u00a0 , Chicago, IL , Italy"},{"name":"Rush University Medical Center \u00a0 , Chicago, IL , Italy"},{"name":"Department of Urology \u00a0 , Chicago, IL , Italy"},{"name":"Rush University Medical Center \u00a0 , Chicago, IL , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Chicago, IL , Italy"},{"name":"Rush University Medical Center \u00a0 , Chicago, IL , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"key":"2024032602363199900_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s11934-012-0258-9","article-title":"Stuttering priapism: Insights into pathogenesis and management","volume":"13","author":"Morrison","year":"2012","journal-title":"Curr Urol Rep"},{"key":"2024032602363199900_bib2","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism","volume":"170","author":"Montague","year":"2003","journal-title":"J Urol"},{"key":"2024032602363199900_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/aja.2011.114","article-title":"Medical management of ischemic stuttering priapism: A contemporary review of the literature","volume":"14","author":"Levey","year":"2012","journal-title":"Asian J Androl"},{"key":"2024032602363199900_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2012.02707.x","article-title":"Standard operating procedures for priapism","volume":"10","author":"Burnett","year":"2013","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11934-006-0061-6","article-title":"Priapism: New concepts in the pathophysiology and new treatment strategies","volume":"7","author":"Bivalacqua","year":"2006","journal-title":"Curr Urol Rep"},{"key":"2024032602363199900_bib6","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1073\/pnas.0407183102","article-title":"Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism","volume":"102","author":"Champion","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024032602363199900_bib7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1464-410X.2002.03022.x","article-title":"Priapism in sickle-cell disease; incidence, risk factors and complications\u2014An international multicentre study","volume":"90","author":"Adeyoju","year":"2002","journal-title":"BJU Int"},{"key":"2024032602363199900_bib8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/archinte.1980.00330220022011","article-title":"Priapism and impotence in homozygous sickle cell disease","volume":"140","author":"Emond","year":"1980","journal-title":"Arch Intern Med"},{"key":"2024032602363199900_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00043426-199911000-00013","article-title":"Prevalence of priapism in children and adolescents with sickle cell anemias","volume":"21","author":"Mantadakis","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"2024032602363199900_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1743-6109.2011.02286.x","article-title":"Sickle-cell priapism\u2014A series of informational articles and a call to action by the medical community","volume":"9","author":"Lewis","year":"2012","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1743-6109.2011.02317.x","article-title":"Priapism and sickle-cell anemia: Diagnosis and nonsurgical therapy","volume":"9","author":"Broderick","year":"2012","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1743-6109.2007.00631.x","article-title":"Glucose-6-phosphate dehydrogenase deficiency: An etiology for idiopathic priapism?","volume":"5","author":"Burnett","year":"2008","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1743-6109.2005.00095.x","article-title":"Testosterone and sleep-related erections: An overview","volume":"2","author":"Montorsi","year":"2005","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1743-6109.2005.00094.x","article-title":"The physiological role of androgens in penile erection: Regulation of corpus cavernosum structure and function","volume":"2","author":"Granata","year":"2005","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/j.1939-4640.1997.tb01967.x","article-title":"Relationship between sleep-related erections and testosterone levels in men","volume":"18","author":"Granata","year":"1997","journal-title":"J Androl"},{"key":"2024032602363199900_bib16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2009.06.040","article-title":"Ketoconazole and prednisone to prevent recurrent ischemic priapism","volume":"182","author":"Abern","year":"2009","journal-title":"J Urol"},{"key":"2024032602363199900_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.1989.7.8.1093","article-title":"High dose ketoconazole in advanced hormone-refractory prostate cancer: Endocrinologic and clinical effects","volume":"7","author":"Trump","year":"1989","journal-title":"Am Soc Clin Oncol"},{"key":"2024032602363199900_bib18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","article-title":"Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer","volume":"168","author":"Harris","year":"2002","journal-title":"J Urol"},{"key":"2024032602363199900_bib19","article-title":"Ketoconazole (systemic): Drug information","volume-title":"UpToDate","author":"Basow","year":"2013"},{"key":"2024032602363199900_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2024032602363199900_bib21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/jcem-57-4-732","article-title":"Site of action of low dose ketoconazole on androgen biosynthesis in men","volume":"57","author":"Santen","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032602363199900_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.urology.2009.04.071","article-title":"Treatment of recurrent priapism in sickle cell anemia with finasteride: A new approach","volume":"74","author":"Rachid-Filho","year":"2009","journal-title":"Urology"},{"key":"2024032602363199900_bib23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1590\/S1677-55382012000500014","article-title":"Finasteride for recurrent priapism in children and adolescents: A report on 5 cases","volume":"38","author":"Barroso","year":"2012","journal-title":"Int Braz J Urol"},{"key":"2024032602363199900_bib24","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss","volume":"8","author":"Irwig","year":"2011","journal-title":"J Sex Med"},{"key":"2024032602363199900_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.urology.2005.11.045","article-title":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","volume":"67","author":"Burnett","year":"2006","journal-title":"Urology"},{"key":"2024032602363199900_bib26","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1046\/j.1432-1327.2001.02233.x","article-title":"Allosteric sites of phosphodiesterase-5 (PDE5): A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum","volume":"268","author":"Gopal","year":"2001","journal-title":"Eur J Biochem"},{"key":"2024032602363199900_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.56.1.124","article-title":"Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds","volume":"56","author":"Turko","year":"1999","journal-title":"Mol Pharacol"},{"key":"2024032602363199900_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/01.ju.0000075500.11519.e8","article-title":"Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism","volume":"170","author":"Lin","year":"2003","journal-title":"J Urol"},{"key":"2024032602363199900_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/mol.104.010678","article-title":"Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation","volume":"68","author":"Musicki","year":"2005","journal-title":"Mol Pharmacol"},{"key":"2024032602363199900_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0002-9343(02)01165-8","article-title":"Sildenafil relieves priapism in patients with sickle cell disease","volume":"113","author":"Bialecki","year":"2002","journal-title":"Am J Med"},{"key":"2024032602363199900_bib31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.urology.2004.12.003","article-title":"Intracavernosal etilefrine self-injection therapy for recurrent priapism: One decade of follow-up","volume":"65","author":"Teloken","year":"2005","journal-title":"Urology"},{"key":"2024032602363199900_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/adc.85.1.52","article-title":"Management of sickle cell priapism with etilefrine","volume":"85","author":"Gbadoe","year":"2001","journal-title":"Arch Dis Child"},{"key":"2024032602363199900_bib33","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1046\/j.1365-2141.2002.03691.x","article-title":"Etilefine for the prevention of priapism in adult sickle cell disease","volume":"118","author":"Okpala","year":"2002","journal-title":"Br J Haematol"},{"key":"2024032602363199900_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0090-4295(96)00027-1","article-title":"Preventive treatment of priapism in sickle cell disease with oral and self administered intracavernous injection of etilefrine","volume":"47","author":"Virag","year":"1996","journal-title":"Urology"},{"key":"2024032602363199900_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00005392-199501000-00054","article-title":"Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue","volume":"153","author":"Steinberg","year":"1995","journal-title":"J Urol"},{"key":"2024032602363199900_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000464011","article-title":"Intracorporeal self-injection with epinephrine as treatment for idiopathic recurrent priapism","volume":"17","author":"van Driel","year":"1990","journal-title":"Eur Urol"},{"key":"2024032602363199900_bib37","first-page":"183","article-title":"\u201cNationwide emergency department visits for priapism in the United States.\u201d Proceedings of the world meeting on sexual medicine, Chicago, USA","volume":"9","author":"Flum","year":"2012","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515305506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515305506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/11\/1\/197\/48359697\/jsm_11_1_197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/11\/1\/197\/48359697\/jsm_11_1_197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T03:12:21Z","timestamp":1711422741000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/11\/1\/197\/6958316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,1]]},"published-print":{"date-parts":[[2014,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12359","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,1]]},"published":{"date-parts":[[2014,1,1]]}}}